HPV Vaccine Reduces Cancer Risk in Young Men

Why this is here: The analysis included data from 615,155 vaccinated boys and men and around 2.3 million unvaccinated individuals, providing a broad base for the findings.

Taito Kitano of Johns Hopkins Bloomberg School of Public Health and a co-author from Nara Medical Center in Japan analyzed data from roughly 2.9 million people in the United States. The researchers examined the connection between HPV vaccination and cancer diagnoses in boys and men aged nine to 26.

They found that vaccinated participants experienced about 46% fewer HPV-related cancers overall. This protective effect remained consistent across age groups, with a roughly 42% reduction observed in those aged nine to 14.

About 80% of sexually active people contract HPV during their lives. The virus can sometimes persist despite immune system response, creating cancer risks including cervical, anal, and head/neck cancers. Currently, just under half of people over 14 in Austria are protected through vaccination.

The study acknowledges that data on the vaccine’s effectiveness against cancers beyond cervical cancer emerged later. Further research is needed to understand long-term impacts and optimal vaccination strategies.